Glenn Bubley MD

Oncology•Boston, MA

Associate Professor of Medicine, Beth Israel Deaconess Medical Center

Join to View Full Profile

330 Brookline AveHim-1049Boston, MA 02215
Phone+1 617-667-5288
Fax+1 617-667-1009

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1980 - 1985
University of ConnecticutResidency, Internal Medicine, 1977 - 1980
Michigan State University College of Human MedicineClass of 1977

Certifications & Licensure

MA State Medical License 1980 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Boston Magazine Castle Connolly, 2008-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Join now to see all

Clinical Trials

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer Start of enrollment: 2009 Sep 29
Terminated
Phase 1, Phase 2
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer Start of enrollment: 2001 Jan 01
Completed
Phase 2
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
BKM120+Abiraterone Acetate for Metastatic CRPC Start of enrollment: 2012 Nov 01
Terminated
Phase 1
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Start of enrollment: 2013 Sep 13
Completed
Phase 2
Enzalutamide + External Beam Rt For Prostate Start of enrollment: 2014 Feb 01
Completed
Phase 2
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer Start of enrollment: 2017 Jun 23
Terminated
Phase 2
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC Start of enrollment: 2017 Jun 09
COMPLETED
PHASE2
Nivolumab Combined with Ipilimumab for Patients with Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
ACTIVE_NOT_RECRUITING
PHASE2
INTREPId (INTermediate Risk Erection PreservatIon Trial) Start of enrollment: 2020 Jun 01
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

2 citations
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Atish D Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M Allaire, Jaqueline Marquez
Cancer Immunology Research. 2024-06-04
6 citations
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable ...
Rana R McKay, Wanling Xie, Xiaoyu Yang, Andres Acosta, Dana Rathkopf
Cancer. 2024-05-01
1 citations
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
Praful Ravi, Lucia Kwak, Wout Devlies, Wanling Xie, Fallon Chipidza
The Prostate. 2024-03-01

Other

Effects of cytotoxic agents on gonadal function in adult men
Bubley GJ, Hayes FJ
http://www.uptodate.com/contents/effects-of-cytotoxic-agents-on-gonadal-function-in-adult-men
UpToDate, Wolters Kluwer Health - 2013-01-04

Press Mentions

Promising Clinical Trials Coming in 2016 for IBD, Prostate Cancer and Spinal Cord InjuriesDecember 15th, 2015
Testing Prostate Cancer Therapies Using a Co-Clinical TrialNovember 16th, 2015
Upcoming Webinar to Provide an Overview and Guide to Clinical Trial Endpoint AdjudicationOctober 27th, 2015